Previous 10 | Next 10 |
2024-05-03 13:17:33 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The P...
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...
2024-02-14 07:50:48 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...
2024-02-14 07:37:32 ET More on Sonnet BioTherapeutics Seeking Alpha’s Quant Rating on Sonnet BioTherapeutics Historical earnings data for Sonnet BioTherapeutics Financial information for Sonnet BioTherapeutics Read the full article on Seeking Alpha ...
Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering Extensive preclinical data on SON-1210 published in Frontiers in Immunology Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expecte...
Verde Clean Fuels Inc. (VGAS) is expected to report for Q4 2023 Pioneer Bancorp Inc. (PBFS) is expected to report for Q2 2024 Equity Commonwealth of Beneficial Interest (EQC) is expected to report $0.27 for Q4 2023 monday.com Ltd. (MNDY) is expected to report $-0.31 for Q4 2023 As...
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
Sonnet BioTherapeutics Holdings Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immed...
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) ...